FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2190659314> ?p ?o ?g. }

• W2190659314 endingPage "199" @default.
• W2190659314 startingPage "193" @default.
• W2190659314 abstract "Background Clear guidelines for the investigation of occult malignancy after unprovoked venous thromboembolism are not yet available. 18F-fluorodeoxyglucose (18F-FDG) PET/CT could serve as a comprehensive screening strategy for occult malignancy in this context. We aimed to compare a screening strategy based on 18F-FDG PET/CT with a limited screening strategy for detection of malignant disease in patients with unprovoked venous thromboembolism. Methods In an open-label, multicentre, randomised study we enrolled patients from four French university hospitals. Patients aged 18 years or older, diagnosed with unprovoked venous thromboembolism (not provoked by a major inherited or acquired risk factor) were invited to participate. Patients were randomly assigned in a 1:1 ratio to a limited screening strategy (physical examination, usual laboratory tests, and basic radiographs) or a screening strategy consisting of the limited strategy plus an 18F-FDG PET/CT scan. Randomisation was done with a dedicated central web-based randomisation system, in block sizes of six, stratified by centre, and concealed from the investigators. Patients and investigators were not masked to study group assignment. Patients were followed up for 2 years. The primary outcome was the proportion of patients with a cancer diagnosis in each group after the initial screening assessment. Analyses were conducted in modified intention-to-test and per-protocol populations. This trial is completed and registered with ClinicalTrials.gov, number NCT00964275. Findings Between March 3, 2009, and Aug 18, 2012, we enrolled and randomly assigned 399 patients; five withdrew consent, leaving 197 in each group for the modified intention-to-test analysis. After initial screening assessment, cancer was diagnosed in 11 (5·6%) patients in the 18F-FDG PET/CT group and four (2·0%) patients in the limited screening group (absolute risk difference 3·6%, 95% CI −0·4 to 7·9; p=0·07). At the initial screening assessment, seven (64%) of the 11 cancers diagnosed in the 18F-FDG PET/CT group were early-stage compared with two of four cancers diagnosed in the limited screening group (p=1·00). One (0·5%) occult malignancy was detected in 186 patients who had negative initial screening in the 18F-FDG PET/CT group, compared with nine (4·7%) in 193 patients in the limited screening group (absolute risk difference 4·1%, 95% CI 0·8 to 8·4, p=0·01). Overall, five (42%) of the 12 cancers diagnosed in the 18F-FDG PET/CT group were advanced stage, compared with seven (54%) of the 13 cancers diagnosed in the limited screening group (p=0·70). 16 patients died during follow-up, eight (4·1%) in each group. Two (1·0%) patients in the 18F-FDG PET/CT group and five (2·5%) in the limited screening group had cancer-related deaths. Interpretation A strategy including limited screening and a 18F-FDG PET/CT was not associated with a significantly higher rate of cancer diagnosis after unprovoked venous thromboembolism. The risk of subsequent cancer diagnosis was, however, lower in patients who had negative initial screening that included 18F-FDG PET/CT than in patients who had negative initial limited screening. Whether or not 18F-FDG PET/CT might be useful in a more selected population of patients with a high risk of cancer remains to be determined. Funding Programme Hospitalier de Recherche Clinique (French Department of Health)." @default.
• W2190659314 created "2016-06-24" @default.
• W2190659314 creator A5000340841 @default.
• W2190659314 creator A5018608064 @default.
• W2190659314 creator A5020323780 @default.
• W2190659314 creator A5021098221 @default.
• W2190659314 creator A5024267268 @default.
• W2190659314 creator A5024382478 @default.
• W2190659314 creator A5024688180 @default.
• W2190659314 creator A5030533594 @default.
• W2190659314 creator A5031298889 @default.
• W2190659314 creator A5040363397 @default.
• W2190659314 creator A5045010479 @default.
• W2190659314 creator A5051047770 @default.
• W2190659314 creator A5076037108 @default.
• W2190659314 creator A5076154316 @default.
• W2190659314 date "2016-02-01" @default.
• W2190659314 modified "2023-10-18" @default.
• W2190659314 title "Limited screening with versus without 18F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial" @default.
• W2190659314 cites W1607273487 @default.
• W2190659314 cites W1967832446 @default.
• W2190659314 cites W2022029942 @default.
• W2190659314 cites W2031109906 @default.
• W2190659314 cites W2040289882 @default.
• W2190659314 cites W2057586524 @default.
• W2190659314 cites W2063853621 @default.
• W2190659314 cites W2065710794 @default.
• W2190659314 cites W2079895099 @default.
• W2190659314 cites W2080860899 @default.
• W2190659314 cites W2113953182 @default.
• W2190659314 cites W2115954565 @default.
• W2190659314 cites W2129625859 @default.
• W2190659314 cites W2131520397 @default.
• W2190659314 cites W2253736303 @default.
• W2190659314 cites W4238943616 @default.
• W2190659314 cites W4253278951 @default.
• W2190659314 cites W4324114153 @default.
• W2190659314 cites W4385969812 @default.
• W2190659314 doi "https://doi.org/10.1016/s1470-2045(15)00480-5" @default.
• W2190659314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26672686" @default.
• W2190659314 hasPublicationYear "2016" @default.
• W2190659314 type Work @default.
• W2190659314 sameAs 2190659314 @default.
• W2190659314 citedByCount "79" @default.
• W2190659314 countsByYear W21906593142016 @default.
• W2190659314 countsByYear W21906593142017 @default.
• W2190659314 countsByYear W21906593142018 @default.
• W2190659314 countsByYear W21906593142019 @default.
• W2190659314 countsByYear W21906593142020 @default.
• W2190659314 countsByYear W21906593142021 @default.
• W2190659314 countsByYear W21906593142022 @default.
• W2190659314 countsByYear W21906593142023 @default.
• W2190659314 crossrefType "journal-article" @default.
• W2190659314 hasAuthorship W2190659314A5000340841 @default.
• W2190659314 hasAuthorship W2190659314A5018608064 @default.
• W2190659314 hasAuthorship W2190659314A5020323780 @default.
• W2190659314 hasAuthorship W2190659314A5021098221 @default.
• W2190659314 hasAuthorship W2190659314A5024267268 @default.
• W2190659314 hasAuthorship W2190659314A5024382478 @default.
• W2190659314 hasAuthorship W2190659314A5024688180 @default.
• W2190659314 hasAuthorship W2190659314A5030533594 @default.
• W2190659314 hasAuthorship W2190659314A5031298889 @default.
• W2190659314 hasAuthorship W2190659314A5040363397 @default.
• W2190659314 hasAuthorship W2190659314A5045010479 @default.
• W2190659314 hasAuthorship W2190659314A5051047770 @default.
• W2190659314 hasAuthorship W2190659314A5076037108 @default.
• W2190659314 hasAuthorship W2190659314A5076154316 @default.
• W2190659314 hasConcept C126322002 @default.
• W2190659314 hasConcept C126838900 @default.
• W2190659314 hasConcept C141071460 @default.
• W2190659314 hasConcept C142724271 @default.
• W2190659314 hasConcept C151730666 @default.
• W2190659314 hasConcept C168563851 @default.
• W2190659314 hasConcept C204787440 @default.
• W2190659314 hasConcept C2779343474 @default.
• W2190659314 hasConcept C2779399171 @default.
• W2190659314 hasConcept C520017518 @default.
• W2190659314 hasConcept C71924100 @default.
• W2190659314 hasConcept C86803240 @default.
• W2190659314 hasConceptScore W2190659314C126322002 @default.
• W2190659314 hasConceptScore W2190659314C126838900 @default.
• W2190659314 hasConceptScore W2190659314C141071460 @default.
• W2190659314 hasConceptScore W2190659314C142724271 @default.
• W2190659314 hasConceptScore W2190659314C151730666 @default.
• W2190659314 hasConceptScore W2190659314C168563851 @default.
• W2190659314 hasConceptScore W2190659314C204787440 @default.
• W2190659314 hasConceptScore W2190659314C2779343474 @default.
• W2190659314 hasConceptScore W2190659314C2779399171 @default.
• W2190659314 hasConceptScore W2190659314C520017518 @default.
• W2190659314 hasConceptScore W2190659314C71924100 @default.
• W2190659314 hasConceptScore W2190659314C86803240 @default.
• W2190659314 hasIssue "2" @default.
• W2190659314 hasLocation W21906593141 @default.
• W2190659314 hasLocation W21906593142 @default.
• W2190659314 hasLocation W21906593143 @default.
• W2190659314 hasOpenAccess W2190659314 @default.
• W2190659314 hasPrimaryLocation W21906593141 @default.
• W2190659314 hasRelatedWork W1973822018 @default.

• next